Literature DB >> 8474155

Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo.

H Bogerd1, W C Greene.   

Abstract

Human T-cell leukemia virus type I (HTLV-I) Rex and human immunodeficiency virus type 1 (HIV-1) Rev are essential gene products required for the replication of these two pathogenic human retroviruses. Both Rex and Rev act at a posttranscriptional level by binding to highly structured RNA-response elements, the Rex-response element in HTLV-I and the Rev-response element in HIV-1. Using a sensitive in vivo assay of protein-protein interaction, we now demonstrate that the HTLV-I Rex and HIV-1 Rev proteins readily form homomultimeric complexes in the absence of their cognate RNA-response elements yet fail to form heteromultimeric complexes with each other. Dominant negative mutations have been identified in both the rex and rev genes which presumably specify a critical activation or effector domain in each of these viral transactivators. Surprisingly, these dominant negative mutants of Rex and Rev fail to interact in vivo. These findings raise the possibility that the binding of nonfunctional monomers rather than functional multimers underlies the transdominant phenotype of these Rex and Rev mutants. Further, it seems likely that the assembly of functional and stable multimers of Rex and Rev in vivo may depend not only on the intrinsic multimerization domains of these proteins but also on the binding of a bridging cellular cofactor to the related activation domains present in each viral transactivator.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474155      PMCID: PMC237568     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Dominant-negative mutants are clustered in a domain of the human T-cell leukemia virus type I Rex protein: implications for trans dominance.

Authors:  I Weichselbraun; J Berger; M Dobrovnik; H Bogerd; R Grassmann; W C Greene; J Hauber; E Böhnlein
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Adult T-cell leukemia: clinical and hematologic features of 16 cases.

Authors:  T Uchiyama; J Yodoi; K Sagawa; K Takatsuki; H Uchino
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

3.  Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen.

Authors:  R E Lanford; J S Butel
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

4.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

5.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

6.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

7.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  An adenovirus type 5 E1A protein with a single amino acid substitution blocks wild-type E1A transactivation.

Authors:  G M Glenn; R P Ricciardi
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  40 in total

1.  Requirements for mouse mammary tumor virus Rem signal peptide processing and function.

Authors:  Hyewon Byun; Nimita Halani; Yongqiang Gou; Andrea K Nash; Mary M Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element.

Authors:  Michael A DiMattia; Norman R Watts; Stephen J Stahl; Christoph Rader; Paul T Wingfield; David I Stuart; Alasdair C Steven; Jonathan M Grimes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

3.  The human T-cell leukemia virus type 1 Rex regulatory protein exhibits an impaired functionality in human lymphoblastoid Jurkat T cells.

Authors:  S Hamaia; H Cassé; L Gazzolo; M Duc Dodon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 4.  The human T-cell leukemia virus Rex protein.

Authors:  Ihab Younis; Patrick L Green
Journal:  Front Biosci       Date:  2005-01-01

5.  Nuclear export and expression of human T-cell leukemia virus type 1 tax/rex mRNA are RxRE/Rex dependent.

Authors:  X T Bai; U Sinha-Datta; N L Ko; M Bellon; C Nicot
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

6.  New approach for inhibiting Rev function and HIV-1 production using the influenza virus NS1 protein.

Authors:  X Y Qian; Z Y Chen; J Zhang; A B Rabson; R M Krug
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

Review 7.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay.

Authors:  H P Bogerd; R A Fridell; R E Benson; J Hua; B R Cullen
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

9.  Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.

Authors:  J Katahira; T Ishizaki; H Sakai; A Adachi; K Yamamoto; H Shida
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Rapid and efficient purification of RNA-binding proteins: application to HIV-1 Rev.

Authors:  Marco Marenchino; David W Armbruster; Mirko Hennig
Journal:  Protein Expr Purif       Date:  2008-09-25       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.